RECRUITINGOBSERVATIONAL

Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis

A Novel Raman Spectroscopy-Based Method for Pan-Cancers Early Diagnosis Supported by Deep Learning: A Prospective, Single-Arm, Multicentre Study

About This Trial

The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer screening. The study includes healthy individuals, patients at risk of cancer, and patients with diagnosed cancers. The main questions it aims to answer are: * Evaluating the deep-learning model's accuracy and specificity in identifying cancer-specific features in Raman spectral data and determining whether this method can accurately classify patients based on risk. * Identifying which model is more adaptable to the Raman spectrum * Providing an interpretable analysis of the model-generated diagnosis Participants are already being diagnosed and follow-up to determine the type of cancer.

Who May Be Eligible (Plain English)

Who May Qualify: - Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer. - Patients in normal physiological conditions without any malignant tumors or precancerous lesions. - Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments. - Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease. Who Should NOT Join This Trial: - Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time - Post-cancer treatment patients. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer. * Patients in normal physiological conditions without any malignant tumors or precancerous lesions. * Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments. * Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease. Exclusion Criteria: * Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time * Post-cancer treatment patients.

Treatments Being Tested

OTHER

No Interventions

All blood samples from participating patients were obtained from routine clinical blood tests conducted during hospital admission or other necessary medical evaluations, followed by serum extraction.